Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib

A method of determining a prognosis of a patient harboring glioblastoma multifonne (GBM) tumor comprising:

• assessing a subcellular concentration or a relative concentration of two or more protein biomarkers selected from a group consisting of EGFR, Src, and NFkB in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
• classifying a patient having a low EGFR level, low Src level and/or low to intermediate NFkB level as having a good prognosis if the patient is treated with radiation therapy combined with gefitinib;
• and
• administering to the patient classified as having a good prognosis radiation therapy in combination with gefitinib.

A method of determining prognosis or relative survival risk of a patient harboring a glioblastoma multiforme (GBM) tumor if the patient is treated with radiation therapy combined with gefitinib comprising:

• assessing a concentration or a relative concentration of two or more biomarkers selected from a group consisting of EGFR, NFkB and Src in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
• classifying a patient with a positive expression of all biomarkers as having a poor prognosis for survival;
• no expression of all biomarkers as having a good prognosis for survival;
• and positive expression of any two biomarkers as having a relatively moderate prognosis for survival, and
• administering to the patient classified as having a good or moderate prognosis radiation therapy in combination with gefitinib.